Concomitant medications particularly other glucose-lowering agents such as insulin or sulphonylureas may increase the risk of hypoglycaemia when used alongside retatrutide
[DOI] [PubMed] [Google Scholar] Besterman HS, Bloom SR, Sarson DL, Blackburn AM, Johnston DI, Patel HR, Stewart JS, Modigliani R, Guerin S, Mallinson CN
Novo's February 2026 announcement of a 50 percent Wegovy list price cut (to $675, effective January 2027) suggests the company is already moving in this direction, though $675 remains well above MFN levels
These medications were originally developed for type 2 diabetes and are now approved for weight management
Stuelsatz, P
Tirzepatide (Mounjaro, Zepbound) operates through dual mechanisms, targeting both GLP-1 and GIP receptors for enhanced insulin and glucagon regulation